Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.

Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed by two-year maintenance with R. Although results of randomized trials confirmed that this approach results in an improved patients' outcome and made a step forward in the management of patients with FL, one important question that can be raised is if this approach is really needed for all patients with FL or if some of them could benefit from a reduced intensity treatment achieving the same results in terms of outcome and survival . This question is of particular interest for newly diagnosed patients for whom maintenance does not affect OS.

More recent data demonstrated that the outcome of patients with FL can be further predicted by evaluating the quality of response to therapy studying minimal residual disease (MRD). This project addresses the objective of evaluating if combining clinical response assessed on FDG-PET scan and molecular response measured through MRD detection could permit to single out groups of patients at different risk of progression and to consequently modulate maintenance therapies, with the aim to provide clinicians a more rational use of the available diagnostic and therapeutic resources.

Study Overview

• Status: Completed
• Conditions: Follicular Non-Hodgkin's Lymphoma
• Intervention / Treatment: Drug: R-CHOP or R-bendamustine; Drug: Standard Maintenance; Drug: Ibritumomab Tiuxetan + Maintenance; Drug: Observation; Drug: Maintenance weekly x4

Detailed Description

This is a multicenter, randomized, phase III, superiority study comparing standard vs response driven approach to maintenance. Adult patients (age ≥ 18 years) with naïve, untreated follicular lymphoma, stage II-IV, Follicular Lymphoma International Prognostic Index 2 (FLIPI2) >0 requiring a therapeutic intervention will be recruited and randomly assigned in a 1:1 ratio to either standard or experimental arm.

All patients will receive the same induction therapy with 6 cycles of R-CHOP or R-bendamustine and 2 additional doses of Rituximab.

At baseline patients will be assessed for molecular status and staged by means of CT scan. A baselineFluorine-18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan should also be performed.

At the end of chemoimmunotherapy all patients will be assessed for disease response by common clinical and laboratory examination, CT scan and FDG-PET. An intermediate assessment of response with CT scan and FDG-PET (optional) will also be performed after the first four courses of R-chemoimmunotherapy.

At the end of induction therapy the status of minimal residual disease will be also evaluated.

After induction treatment all responding patients in the standard arm will receive standard maintenance therapy with Rituximab (every 2 months for 2 years), while patients in the experimental arm will be subdivided into two risk groups and assigned to different post induction treatments based on FDG-PET and MRD results. In both arms, patients with stable or progressive disease (PET positive and less than PR on CT scan) will be addressed to salvage treatment chosen at physician discretion.

In the experimental arm, risk group allocation will be performed primarily on the basis of FDG-PET results:

• Group 1 (low risk): negative FDG-PET
• Group 2 (high risk): positive FDG-PET

Patients at low risk (FDG-PET negative) will received maintenance therapy according to their MRD status,particularly:

• Group 1a (MRD negative): observation
• Group 1b (MRD positive): pre-emptive Rituximab therapy

Patient at high risk (FDG-PET positive) will receive maintenance regardless of their MRD status:

· Group 2: intensified maintenance ((90)Y Ibritumomab Tiuxetan + Rituximab maintenance )

• Study Type: Interventional
• Enrollment (Actual): 807
• Phase: Phase 3

Contacts and Locations

Study Locations

• Italy
  • Alessandria, Italy, 15121
    • Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al)
  • Ancona, Italy, 60126
    • A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona _
  • Bari, Italy, 70124
    • A.O. Universitaria Ospedale Consorziale Policlinico Di Bari
  • Biella, Italy, 13900
    • A.O. Ospedale Degli Infermi
  • Bologna, Italy, 40138
    • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
  • Brescia, Italy, 25125
    • Pres.Ospedal.Spedali Civili Brescia
  • Brindisi, Italy, 72100
    • Stabilimento "Perrino" - Brindisi -
  • Cagliari, Italy, 09121
    • Ospedale Armando Businco - Cagliari
  • Catania, Italy, 95124
    • A.O. Universitaria Ospedale Vittorio Emanuele Di Catania
  • Cuneo, Italy, 12100
    • Azienda Ospedaliera S. Croce E Carle Di Cuneo
  • Firenze, Italy, 50139
    • A.O. Universitaria Careggi Di Firenze
  • Genova, Italy, 16132
    • A.O. Universitaria S. Martino Di Genova
  • Lecce, Italy
    • Ematologia Ospedale Vito Fazzi
  • Matera, Italy, 75100
    • Presidio Ospedaliero - Matera -
  • Messina, Italy, 98158
    • Azienda Ospedaliera Papardo
  • Milano, Italy, 20162
    • Ospedale Ca' Granda-Niguarda
  • Milano, Italy, 20122
    • IRCCS Ospedale Maggiore Policlinico di Milano
  • Modena, Italy, 41124
    • A.O. Universitaria Policlinico Di Modena
  • Napoli, Italy
    • IRCCS Istituto Nazionale Tumori Fondazione Pascale
  • Novara, Italy, 28100
    • A.O. Universitaria Maggiore Della Carita' Di Novara
  • Nuoro, Italy, 08100
    • Ospedale San Francesco
  • Palermo, Italy, 90127
    • A.O. Universitaria Policlinico Giaccone Di Palermo
  • Palermo, Italy, 90146
    • A.O. "V. Cervello"
  • Parma, Italy
    • A O Universitaria di Parma
  • Pavia, Italy, 27100
    • IRCCS Policlinico S. Matteo
  • Perugia, Italy, 06134
    • Azienda Ospedaliera Di Perugia - Ospedale S. Maria Della Misericordia -
  • Pescara, Italy, 65124
    • Ospedale Civile Spirito Santo
  • Piacenza, Italy, 29121
    • AUSL di Piacenza
  • Pisa, Italy, 56126
    • A.O. Universitaria Pisana
  • Reggio Calabria, Italy, 89123
    • Ospedale Bianchi - Melacrino - Morelli
  • Rimini, Italy, 47924
    • Ausl Di Rimini
  • Roma, Italy, 00185
    • Universita' Degli Studi Di Roma 'La Sapienza'
  • San Giovanni Rotondo, Italy
    • Casa Sollievo della Sofferenza
  • Siena, Italy, 53100
    • A.O. Universitaria Senese
  • Torino, Italy, 10126
    • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino
  • Treviso, Italy
    • Ospedale Cà Foncello
  • Tricase (LE), Italy
    • A.O.Cardinale Panico Ematologia e centro trapianti
  • Udine, Italy, 33100
    • A.O. Universitaria S. Maria Della Misericordia Di Udine
  • Varese, Italy, 21100
    • Ospedale di Circolo e Fondazione Macchi
  • Forlì Cesena
    • Meldola, Forlì Cesena, Italy, 47014
      • Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc)
  • MI
    • Milano, MI, Italy, 20133
      • Fondazione IRCCS Milano INT
  • Macerata
    • Civitanova Marche, Macerata, Italy, 62012
      • ASUR 8
  • Milano
    • Rozzano, Milano, Italy, 20089
      • IRCCS Istituto Clinico Humanitas
  • Monza Brianza
    • Monza, Monza Brianza, Italy, 20900
      • Azienda Ospedaliera S. Gerardo di Monza
  • Potenza
    • Rionero in Vulture, Potenza, Italy, 85028
      • Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob)
  • Salerno
    • Nocera Inferiore, Salerno, Italy, 84014
      • P.O. Umberto I
  • TR
    • Terni, TR, Italy, 05100
      • A.O. S. Maria di Terni
  • Torino
    • Candiolo, Torino, Italy, 10060
      • Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histological diagnosis of B-Cell CD20+ Follicular Lymphoma (FL), grade I, II, IIIa according to the WHO 2008 classification
• ECOG performance status 0-2
• Age ≥ 18 years
• Ann Arbor stage II-IV
• FLIPI2>0
• Presence of evaluable/measurable disease after diagnostic biopsy

• At least one of the following criteria for defining active disease:

  • systemic symptoms
  • cytopenia due to bone marrow involvement
  • LDH> upper normal value
  • any nodal or extranodal tumor mass with a diameter >7cm
  • involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3cm
  • extranodal disease
  • rapidly progressive disease
• Life expectancy > 6 months
• Left ventricular ejection fraction (LVEF) ³ 50%
• Serum negativity for HIV
• Serum negativity for HBsAg; HBcAb positive but HBV-DNA negative patients are allowed with mandatory Lamivudine prophylaxis.
• Serum negativity for HCV, except for those patients without signs of active viral replication assessed by HCV-RNA copies
• Serum creatinine < 2mg/dl , serum bilirubin < 1.5mg/dl, aspartate amino-transferase (AST/GOT) £ 2.5xUNV, alanine amino-transferase (ALT/GPT) £ 2.5xUNV, and alkaline phosphatase £ 4 times the upper limit of normal (unless the increase is attributed directly to the presence of tumour by the Investigator)
• Patients with no previous treatment for the lymphoma with the exception of locoregional radiotherapy (IFRT)
• Adequate measure adoption to avoid pregnancy
• Written informed consent given at time of registration
• Patient must be accessible for treatment and follow up.

Exclusion Criteria:

• Histological diagnosis of :

  • any lymphoma other than follicular lymphoma and all CD20 negative B-cell lymphomas
  • grade III b follicular lymphoma
  • evidence of transformation to high grade lymphoma
• Ann Arbor stage I
• Suspect or clinical evidence of CNS involvement by lymphoma
• History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis DCIS of the breast treated with lumpectomy alone with curative intent
• Evidence of any severe active acute or chronic infection
• Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy
• Severe chronic obstructive pulmonary disease with hypoxemia
• Severe diabetes mellitus difficult to control with adequate insulin therapy
• Myocardial infarction within 6 months before study entry
• Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension, (resting diastolic blood pressure >115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV
• HbsAg-positive, HIV-positive, or HCVAb-positive patients
• Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
• Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
• Follicular lymphoma, showing a negative baseline PET scan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: GROUP 1 - STANDARD; R-CHOP or R-bendamustine + Standard Maintenance	Drug: R-CHOP or R-bendamustine; As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.; Other Names: Rituximab; Oncovin; Prednisone; Hydroxydaunorubicin; Bendamustine; Cyclophosphamide,; Drug: Standard Maintenance; Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.; Other Names: Rituximab
EXPERIMENTAL: GROUP 2; FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance	Drug: R-CHOP or R-bendamustine; As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.; Other Names: Rituximab; Oncovin; Prednisone; Hydroxydaunorubicin; Bendamustine; Cyclophosphamide,; Drug: Ibritumomab Tiuxetan + Maintenance; single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.; Other Names: Ibritumomab Tiuxetan
EXPERIMENTAL: GROUP 1a; FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation	Drug: R-CHOP or R-bendamustine; As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.; Other Names: Rituximab; Oncovin; Prednisone; Hydroxydaunorubicin; Bendamustine; Cyclophosphamide,; Drug: Observation; not maintenance therapy and followed-up with MRD monitoring.
EXPERIMENTAL: GROUP 1b; FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4	Drug: R-CHOP or R-bendamustine; As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.; Other Names: Rituximab; Oncovin; Prednisone; Hydroxydaunorubicin; Bendamustine; Cyclophosphamide,; Drug: Maintenance weekly x4; Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses; Other Names: Rituximab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS	To evaluate whether a FDG-PET and MRD response-based maintenance therapy is more effective in terms of Progression-Free Survival (PFS) than a standard maintenance therapy with Rituximab in patients with untreated, advanced, follicular lymphoma. Progression Free Survival (PFS) PFS will be measured from the date of randomization to the date of documented first occurrence of disease progression or relapse or to the date of death from any cause. Responding patients and patients who are lost to follow up will be censored at their last assessment date.	12/31/2019

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CRR	Complete Response Rate (CRR) is defined as the number of CR after the completion of the study treatment. Patients without a response assessment (due to any reasons) will be considered as non-responders.	12/31/2019
ORR	Overall Response Rate (ORR) after the completion of the treatment, defined as the sum of Complete Response and Partial Response. Patients without a response assessment (due to any reasons) will be considered as non-responders.	12/31/2019
DR	Duration of Response (DR) is from the time when criteria for response (ie, CR or PR) are met, to the first documentation of relapse or progression.	12/31/2019
EFS	Event Free Survival (EFS) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death).	12/31/2019
OS	Overall survival (OS) is defined as the time from the first day of study treatment until the date of death irrespective of cause. Patients who have not died at the time of end of the whole study , and patients who are lost to follow up , will be censored at the date of the last contact.	12/31/2019
Molecular response analysis	Rate of molecular remission will be defined as the proportion of patients polymerase chain reaction (PCR) negative for Bcl2/IgH at different time-points including those achieving continuous MR in two or more consecutive time-points. Patients without a response assessment (due to any reasons) will be excluded from the analysis.; Rate of conversion will be defined as the proportion of patients from baseline PCR-positivity to PCR-negativity. Patients without a response assessment (due to any reasons) will be excluded from the analysis.; Rate of molecular relapse will be defined as the proportion of patients from PCR-negativity to PCR-positivity. Patients without a response assessment (due to any reasons) will be excluded from the analysis.	12/31/2019

Collaborators and Investigators

• Sponsor: Fondazione Italiana Linfomi ONLUS
• Investigators: Principal Investigator: Donato Mannina, MD, Hematology, Azienda Ospedali Riuniti Papardo-Piemonte, Messina, Italy.; Principal Investigator: Massimo Federico, MD, Department of Diagnostic Medicine, Clinical Medicine and Public Health, University of Modena and Reggio Emilia, Modena , Italy

Publications and helpful links

General Publications

• Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28.

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (ACTUAL): December 1, 2021
• Study Completion (ACTUAL): December 1, 2021

Study Registration Dates

• First Submitted: November 21, 2013
• First Submitted That Met QC Criteria: February 13, 2014
• First Posted (ESTIMATE): February 14, 2014

Study Record Updates

• Last Update Posted (ACTUAL): June 21, 2022
• Last Update Submitted That Met QC Criteria: June 16, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Follicular; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Cyclophosphamide; Bendamustine Hydrochloride; Rituximab; Prednisone; Antibodies, Monoclonal
• Other Study ID Numbers: FIL_FOLL12